2025
Accuracy of COVID-19 vaccination Self-report compared with data from VSD electronic health Records for Pregnant Women and non-pregnant Adults, 2021-2022
Stein A, Williams J, Hurley L, Breslin K, Kurlandsky K, Hambidge S, Nelson J, Fuller C, Crane B, Hanson K, Glenn S, Jazwa A, Reifler L. Accuracy of COVID-19 vaccination Self-report compared with data from VSD electronic health Records for Pregnant Women and non-pregnant Adults, 2021-2022. American Journal Of Epidemiology 2025, kwaf112. PMID: 40445214, DOI: 10.1093/aje/kwaf112.Peer-Reviewed Original ResearchElectronic health record dataElectronic health recordsSelf-ReportHealth recordsVaccine Safety DatalinkAccuracy of electronic health recordsPregnant womenNon-pregnant adultsNon-Hispanic blacksSpanish-speaking respondentsVaccination statusEstimate vaccination ratesNon-pregnant peopleCross-sectional studySelf-reported vaccination statusSelf-reported dataSelf-report measuresAdult respondentsPrevention effortsVaccination ratesEstimates of sensitivityVaccination dataCOVID-19COVID-19 pandemicVaccination coverage
2024
Trends in COVID‐19–Attributable Hospitalizations Among Adults With Laboratory‐Confirmed SARS‐CoV‐2—COVID‐NET, June 2020 to September 2023
Taylor C, Whitaker M, Patton M, Melgar M, Kirley P, Kawasaki B, Yousey‐Hindes K, Openo K, Ryan P, Kim S, Como‐Sabetti K, Solhtalab D, Barney G, Tesini B, Moran N, Sutton M, Talbot H, Olsen K, Havers F. Trends in COVID‐19–Attributable Hospitalizations Among Adults With Laboratory‐Confirmed SARS‐CoV‐2—COVID‐NET, June 2020 to September 2023. Influenza And Other Respiratory Viruses 2024, 18: e70021. PMID: 39496579, PMCID: PMC11534501, DOI: 10.1111/irv.70021.Peer-Reviewed Original Research
2022
Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review
Guo P, Furnary T, Vasiliou V, Yan Q, Nyhan K, Jones DP, Johnson CH, Liew Z. Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review. Environment International 2022, 162: 107159. PMID: 35231839, PMCID: PMC8969205, DOI: 10.1016/j.envint.2022.107159.Peer-Reviewed Original ResearchConceptsPolyfluoroalkyl substances (PFAS) exposureSubstance exposurePFAS exposureNon-pregnant adultsNon-targeted metabolomicsLiquid chromatography-mass spectrometryHigh-resolution liquid chromatography-mass spectrometryFatty acid oxidationChromatography-mass spectrometryPregnant womenBiological membrane functionMetabolic pathway alterationsEpidemiological studiesTryptophan metabolismHuman studiesMetabolomic signaturePathway alterationsLipid metabolismLipid metabolitesGlycerophospholipid metabolismProspective designHuman physiological changesMetabolomic profilesAnalytical platformMetabolome changes
2018
Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLOS Medicine 2018, 15: e1002579. PMID: 29894518, PMCID: PMC5997317, DOI: 10.1371/journal.pmed.1002579.Peer-Reviewed Original ResearchConceptsPregnant womenArtemether-lumefantrineCure rateClinical studiesYoung childrenCurrent standard treatment regimenUncomplicated Plasmodium falciparum malariaPharmacokinetic modelAbsorption of lumefantrinePre-treatment parasitaemiaVenous plasma dataAlternative dosing regimensPlasmodium falciparum malariaStandard treatment regimenProspective clinical studyNon-pregnant adultsLow cure ratePopulation pharmacokinetic modelRelevant clinical studiesUseful therapeutic lifeFrequency of dosingConcentration-time dataHigher individual dosesLumefantrine exposureLumefantrine levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply